期刊
FRONTIERS IN MEDICINE
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2022.963540
关键词
rheumatoid arthritis; biomarker; haptoglobin; orosomucoid 1; multiple reaction monitoring
资金
- Instituto de Salud Carlos III
- RETIC-RIER [PI16/02124, PI19/01206, PI20/00793]
- RICORS-REI [RD16/0012/0002]
- European Regional Development Fund/European Social Fund [RD21/0002/0009]
- AE CICA-INIBIC
- Xunta de Galicia [ED431E 2018/03]
- Contrato PTA [IN607A2021/07, IN607D2020/10]
- Ministerio de Ciencia, Innovacion y Universidades [PTA2017-14846-I]
- Contrato Sara Borrell
- Fondo de Investigacion Sanitaria [CD19/00229]
- Universidade da Coruna/CISUG
- ISCIII
This study utilizes a proteomic biomarker pipeline to analyze the molecular changes associated with the RF and ACPA status of rheumatoid arthritis patients. The results identify specific proteins that show altered abundance in relation to RF and ACPA status, and two putative biomarkers, A1AG1 and HPT, are validated as increased in the double seropositive group. These findings provide valuable information for the stratification and personalized medicine of rheumatoid arthritis patients.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and presence of systemic autoantibodies, with a great clinical and molecular heterogeneity. Rheumatoid Factor (RF) and anti-citrullinated protein antibodies (ACPA) are routinely used for the diagnosis of RA. However, additional serological markers are needed to improve the clinical management of this disease, allowing for better patient stratification and the desirable application of precision medicine strategies. In the present study, we investigated those systemic molecular changes that are associated with the RF and ACPA status of RA patients. To achieve this objective, we followed a proteomic biomarker pipeline from the discovery phase to validation. First, we performed an iTRAQ-based quantitative proteomic experiment on serum samples from the RA cohort of the Hospital of Santiago de Compostela (CHUS). In this discovery phase, serum samples from the CHUS cohort were pooled according to their RF/ACPA status. Shotgun analysis revealed that, in comparison with the double negative group (RF-/ACPA-), the abundance of 12 proteins was altered in the RF+/ACPA+ pool, 16 in the RF+/ACPA- pool and 10 in the RF-/ACPA+ pool. Vitamin D binding protein and haptoglobin were the unique proteins increased in all the comparisons. For the verification phase, 80 samples from the same cohort were analyzed individually. To this end, we developed a Multiple Reaction Monitoring (MRM) method that was employed in a comprehensive targeted analysis with the aim of verifying the results obtained in the discovery phase. Thirty-one peptides belonging to 12 proteins associated with RF and/or ACPA status were quantified by MRM. In a final validation phase, the serum levels of alpha-1-acid glycoprotein 1 (A1AG1), haptoglobin (HPT) and retinol-binding protein 4 (RET4) were measured by immunoassays in the RA cohort of the Hospital of A Coruna (HUAC). The increase of two of these putative biomarkers in the double seropositive group was validated in 260 patients from this cohort (p = 0.009 A1AG1; p = 0.003 HPT). The increased level of A1AG1 showed association with RF rather than ACPA (p = 0.023), whereas HPT showed association with ACPA rather than RF (p = 0.013). Altogether, this study has allowed a further classification of the RA seropositive patients into two novel clusters: RF+A1AG+ and ACPA+HPT+. The determination of A1AG1 and HPT in serum would provide novel information useful for RA patient stratification, which could facilitate the effective implementation of personalized medicine in routine clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据